H1B Report
Side-by-side comparison

Roswell Park Cancer Institute vs WIPRO LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Roswell Park Cancer Institute
NYRank #FEIN 16-1552370
Entity B
WIPRO LIMITED
NJRank #6FEIN 98-0154401

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricRoswell Park Cancer InstituteWIPRO LIMITED
Total filings24772,392
Certified %89.88%91.61%
Denied %4.05%0.37%
Withdrawn %1.62%1.37%
Cert-withdrawn %4.45%6.64%
Rank#6
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateNYNJ

Outcomes — Roswell Park Cancer Institute

DOL case-status mix.

Outcome breakdown: Certified 89.9%, Cert-withdrawn 4.5%, Withdrawn 1.6%, Denied 4.0%
Outcome breakdown
OutcomeShare
Certified89.9%
Cert-withdrawn4.5%
Withdrawn1.6%
Denied4.0%
Certified89.9%
Cert-withdrawn4.5%
Withdrawn1.6%
Denied4.0%

Outcomes — WIPRO LIMITED

DOL case-status mix.

Outcome breakdown: Certified 91.6%, Cert-withdrawn 6.6%, Withdrawn 1.4%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Roswell Park Cancer Institute
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201018
FY201114
FY201223
FY201324
FY201419
FY20158
FY201620
FY20179
FY20186
FY201914
FY20200
FY20210
FY20220
FY20234
FY202418
FY202552
FY202618
WIPRO LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20103,039
FY20113,025
FY20127,031
FY20136,574
FY20148,104
FY201511,824
FY201610,254
FY20175,012
FY20186,067
FY20194,154
FY202094
FY2021128
FY202297
FY2023554
FY20242,296
FY20252,289
FY20261,850

Top 5 occupations — Roswell Park Cancer Institute

Top 5 occupations — WIPRO LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.